← Monday 26 Octobernote 7 of 12
Health researchMon 26 Oct 2026 · 7 of 12

Bispecific ADC doubles PFS in HR+/HER2‑ breast cancer

Verified · 4/4 supported1 cited · 1 min read

Clinical Trials Arena reports that an $8.4bn bispecific ADC doubles progression‑free survival in HR+/HER2‑ breast cancer . Clinical Trials Arena reports that bispecific ADCs are viewed as the next generation of ADC development . Clinical Trials Arena reports that they continue to be the focus of high‑value dealmaking .

Why it matters. Clinical Trials Arena reports that the doubled PFS could benefit patients with HR+/HER2‑ breast cancer .

Earlier on Health research

Sun 25 Oct 2026Johns Hopkins APL's OsteoSEE Wins R&D 100 Award for Early Fracture DetectionMedical Xpress reports that researchers at Johns Hopkins Applied Physics Laboratory have developed Osteo Surface Echo Evaluation (OsteoSEE), a noninvasive ultrasound-based platform that uses surface acoustic waves to detect microstructural changes and early-stage tibial stress fractures. Medical Xpress reports that OsteoSEE avoids the use of ionizing radiation in fracture detection. Medical Xpress reports that the technology was named a 2026 R&D 100 Award winner. Medical Xpress reports that Anna Knight, the principal investigator, highlighted the platform's potential to support military readiness by enabling earlier detection of common overuse injuries in personnel.Sun 25 Oct 2026SGLT2 Inhibitors Show Mortality and Kidney Benefits but Higher Cardiac Risks in Adults 80+ with CKDMedical Xpress reports that the analysis used electronic health records of 10,076 adults aged 80 years or older with chronic kidney disease. Medical Xpress reports that initiating SGLT2 inhibitor therapy was linked to an 18% reduction in all‑cause mortality over a two‑year follow‑up. Medical Xpress reports that the same therapy was linked to a 22% reduction in major adverse kidney events over the same period. Medical Xpress reports that SGLT2 inhibitors showed no significant effect on major adverse cardiovascular events overall, but were associated with higher risks of specific cardiac events such as heart attacks and acute heart failure. Medical Xpress reports that SGLT2 inhibitors were also associated with a higher risk of acute kidney injury, and the findings will be presented at ASN Kidney Week 2026 on October 22–25.Sat 24 Oct 2026UCL trial shows abiraterone may halve death risk in high‑risk localized prostate cancerMedical Xpress reports that prostate cancer is the most common cancer in men, affecting more than 1 million men worldwide in 2013. Medical Xpress notes that treating the disease more aggressively than necessary is linked to increased side effects and poorer quality of life. Medical Xpress says doctors must balance identifying patients who need intensive treatment with those who may do well with less aggressive therapy. Medical Xpress reports that at a major cancer conference in Madrid, a University College London team presented STAMPEDE trial results showing that adding the hormone therapy abiraterone to standard treatment for men with high‑risk, localized prostate cancer could halve the risk of death. Medical Xpress adds that the same trial indicated the addition also slowed overall disease progression.
Next · Formula 1Hadjar blames Red Bull clutch design after poor US Grand Prix start →